Valibose, an alpha-glucosidase inhibitor, ameliorates the metabolic disorder of glucose and lipids and the nephropathy in streptozotocin-induced diabetic rats.
- Author:
Quan LIU
1
;
Shuai-Nan LIU
;
Su-Juan SUN
;
Zhu-Fang SHEN
Author Information
1. State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
- Publication Type:Journal Article
- MeSH:
Acetylglucosaminidase;
blood;
Animals;
Blood Glucose;
metabolism;
Blood Urea Nitrogen;
Cholesterol;
blood;
Creatinine;
blood;
Cyclohexanols;
pharmacology;
Diabetes Mellitus, Experimental;
blood;
pathology;
Diabetic Nephropathies;
prevention & control;
Enzyme Inhibitors;
pharmacology;
Fructosamine;
blood;
Glycoside Hydrolase Inhibitors;
Hyperglycemia;
prevention & control;
Hypoglycemic Agents;
pharmacology;
Kidney;
pathology;
Male;
Rats;
Rats, Sprague-Dawley;
Triglycerides;
blood;
Weight Gain;
drug effects
- From:
Acta Pharmaceutica Sinica
2013;48(8):1227-1232
- CountryChina
- Language:Chinese
-
Abstract:
This study is to evaluate the anti-diabetic effects of the alpha-glucosidase inhibitor valibose in a streptozotocin (STZ)-induced type 1 diabetes rat model. Diabetes was induced by a single dose of STZ (58 mg x kg(-1), ip) in SD rats, rats with elevated fasting blood glucose levels (250-450 mg x dL(-1)) were selected and divided into five groups (n = 10 in each). Another ten normal SD rats were chosen as normal group. Valibose mixed with the high sucrose diets (0.4, 1.0 and 2.5 mg 100 g(-1) diets) or acarbose (30 mg x 100 g(-1) diets) was administrated in the diabetic rats for about 5 weeks. In all groups, fasting and postprandial plasma glucose, plasma lipids, glycosylated serum protein, N-acetyl-beta-D-glucosaminidase (NAG), creatinine (Cre), blood urea nitrogen (BUN) and urine sugar levels were determined during the treatment. At the end of the experiment, the morphological alterations in kidney were evaluated by hematoxylin-eosin (HE) staining. After 3-weeks administration, valibose significantly decreased postprandial and fasting blood glucose, urine glucose, and reduced the levels of serum fructosamine. Valibose also decreased plasma triglyceride and cholesterol levels after 4 weeks treatment. These results indicated that valibose ameliorated metabolic disturbance of glucose and lipids in STZ-induced diabetic rats. In addition, valibose markedly reduced level of serum NAG and BUN, and decreased the weight index of kidney. HE staining showed reduced kidney pathological changes after valibose treatment. The findings of the present study indicate that valibose may be a novel alpha-glucosidase inhibitor for the prevention from hyperglycemia in STZ-induced type 1 diabetes rats. And valibose might have a potential role for protecting against diabetic nephropathy during hyperglycemia.
